Pathophysiology of hypertriglyceridemia

H. C. Hassing; R. P. Surendran; H. L. Mooij; E. S. Stroes; M. Nieuwdorp; G. M. Dallinga-Thie

doi:https://doi.org/10.1016/j.bbalip.2011.11.010

Pathophysiology of hypertriglyceridemia

H. C. Hassing, R. P. Surendran, H. L. Mooij, E. S. Stroes, M. Nieuwdorp, G. M. Dallinga-Thie

Research output: Contribution to journal › Review article › Academic › peer-review

57 Citations (Scopus)

Abstract

The importance of triglycerides as risk factor for CVD is currently under debate. The international guidelines do not include TG into their risk calculator despite the recent observations that plasma TG is an independent risk factor for CVD. The understanding of the pathophysiology of triglycerides opens up avenues for development of new drug targets. Hypertriglyceridemia occurs through I. Abnormalities in hepatic VLDL production, and intestinal chylomicron synthesis 2. Dysfunctional LPL-mediated lipolysis or 3. Impaired remnant clearance. The current review will discuss new aspects in lipolysis by discussing the role of GPIHBP1 and the involvement of apolipoproteins and in the process of hepatic remnant clearance with a focus upon the role of heparin sulfate proteoglycans. Finally we will shortly discuss future perspectives for novel therapies aiming at improving triglyceride homeostasis. This article is part of a Special Issue entitled Triglyceride Metabolism and Disease. (C) 2011 Elsevier B.V. All rights reserved

Original language	English
Pages (from-to)	826-832
Journal	BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
Volume	1821
Issue number	5
DOIs	https://doi.org/10.1016/j.bbalip.2011.11.010
Publication status	Published - 2012

Access to Document

https://doi.org/10.1016/j.bbalip.2011.11.010

Cite this

@article{3c0bf205d603425dbb8ed07a652d00b6,

title = "Pathophysiology of hypertriglyceridemia",

abstract = "The importance of triglycerides as risk factor for CVD is currently under debate. The international guidelines do not include TG into their risk calculator despite the recent observations that plasma TG is an independent risk factor for CVD. The understanding of the pathophysiology of triglycerides opens up avenues for development of new drug targets. Hypertriglyceridemia occurs through I. Abnormalities in hepatic VLDL production, and intestinal chylomicron synthesis 2. Dysfunctional LPL-mediated lipolysis or 3. Impaired remnant clearance. The current review will discuss new aspects in lipolysis by discussing the role of GPIHBP1 and the involvement of apolipoproteins and in the process of hepatic remnant clearance with a focus upon the role of heparin sulfate proteoglycans. Finally we will shortly discuss future perspectives for novel therapies aiming at improving triglyceride homeostasis. This article is part of a Special Issue entitled Triglyceride Metabolism and Disease. (C) 2011 Elsevier B.V. All rights reserved",

author = "Hassing, {H. C.} and Surendran, {R. P.} and Mooij, {H. L.} and Stroes, {E. S.} and M. Nieuwdorp and Dallinga-Thie, {G. M.}",

year = "2012",

doi = "https://doi.org/10.1016/j.bbalip.2011.11.010",

language = "English",

volume = "1821",

pages = "826--832",

journal = "BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS",

issn = "1388-1981",

publisher = "Elsevier",

number = "5",

}

TY - JOUR

T1 - Pathophysiology of hypertriglyceridemia

AU - Hassing, H. C.

AU - Surendran, R. P.

AU - Mooij, H. L.

AU - Stroes, E. S.

AU - Nieuwdorp, M.

AU - Dallinga-Thie, G. M.

PY - 2012

Y1 - 2012

N2 - The importance of triglycerides as risk factor for CVD is currently under debate. The international guidelines do not include TG into their risk calculator despite the recent observations that plasma TG is an independent risk factor for CVD. The understanding of the pathophysiology of triglycerides opens up avenues for development of new drug targets. Hypertriglyceridemia occurs through I. Abnormalities in hepatic VLDL production, and intestinal chylomicron synthesis 2. Dysfunctional LPL-mediated lipolysis or 3. Impaired remnant clearance. The current review will discuss new aspects in lipolysis by discussing the role of GPIHBP1 and the involvement of apolipoproteins and in the process of hepatic remnant clearance with a focus upon the role of heparin sulfate proteoglycans. Finally we will shortly discuss future perspectives for novel therapies aiming at improving triglyceride homeostasis. This article is part of a Special Issue entitled Triglyceride Metabolism and Disease. (C) 2011 Elsevier B.V. All rights reserved

AB - The importance of triglycerides as risk factor for CVD is currently under debate. The international guidelines do not include TG into their risk calculator despite the recent observations that plasma TG is an independent risk factor for CVD. The understanding of the pathophysiology of triglycerides opens up avenues for development of new drug targets. Hypertriglyceridemia occurs through I. Abnormalities in hepatic VLDL production, and intestinal chylomicron synthesis 2. Dysfunctional LPL-mediated lipolysis or 3. Impaired remnant clearance. The current review will discuss new aspects in lipolysis by discussing the role of GPIHBP1 and the involvement of apolipoproteins and in the process of hepatic remnant clearance with a focus upon the role of heparin sulfate proteoglycans. Finally we will shortly discuss future perspectives for novel therapies aiming at improving triglyceride homeostasis. This article is part of a Special Issue entitled Triglyceride Metabolism and Disease. (C) 2011 Elsevier B.V. All rights reserved

U2 - https://doi.org/10.1016/j.bbalip.2011.11.010

DO - https://doi.org/10.1016/j.bbalip.2011.11.010

M3 - Review article

C2 - 22179026

SN - 1388-1981

VL - 1821

SP - 826

EP - 832

JO - BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

JF - BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

IS - 5

ER -